Thumbnail Image
Publication

Corrigendum to pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study

Plimack, ER
; 
Powles, T
; 
Stus, V
; 
Gafanov, R
; 
Nosov, D
; 
Waddell, Tom
; 
Alekseev, B
; 
Poulioti, F
; 
Melichar, B
; 
Soulieres, D
... show 10 more
Citations
Altmetric:
Abstract
Authors
Plimack, ER
Powles, T
Stus, V
Gafanov, R
Nosov, D
Waddell, Tom
Alekseev, B
Poulioti, F
Melichar, B
Soulieres, D
Borchiellini, D
McDermott, RS
Vynnychenko, I
Chang, YH
Tamada, S
Atkins, MB
Li, CX
Perini, R
Molife, LR
Bedke, J
Riniu, BI
Affiliation
The Christie NHS Foundation Trust, Manchester, UK.
Description
Date
2023
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
Found with Open Access Button
Adobe PDF, 315.24 KB
Keywords
Type
Other
Citation
Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, et al. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study ( vol 84 , pg , 449 , 2023). EUROPEAN UROLOGY. 2023 NOV;84(5):E123-E4. PubMed PMID: WOS:001092250500001. English.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626751
Embedded videos